AETHLON MEDICAL INC

Aethlon Medical reported a reduced net loss of $1.55 million for the three months ended June 30, 2026, compared to $1.76 million in the prior year, with operating expenses decreasing by 11.9%. The company strengthened its liquidity by raising $1.82 million net through an at-the-market offering during the quarter and an additional $4.0 million gross in a public offering subsequent to quarter-end. A 1-for-5 reverse stock split was effected in July 2026, and the Australian oncology clinical trial for Hemopurifier is ongoing. Management believes current capital is sufficient for at least 12 months of planned operations.

Aethlon Medical, Inc. announced its financial results for the first fiscal quarter ended June 30, 2026, reporting a net loss attributable to common stockholders of $(1.55) million, an improvement from $(1.76) million in the prior-year quarter. Basic and diluted net loss per share also improved to $(4.02). The company reduced consolidated operating expenses by 11.9% to $1.6 million and reported cash and cash equivalents of $4.9 million. Additionally, Aethlon Medical raised $4.0 million in gross proceeds post-quarter and made significant clinical progress, including dosing the first participant in the final cohort of its Phase 1 oncology study and having a Long COVID manuscript accepted for publication.

Aethlon Medical, Inc. announced a 1-for-5 reverse stock split of its common stock, effective July 31, 2026. The company expects its common stock to begin trading on a split-adjusted basis on The Nasdaq Capital Market on August 4, 2026. This action is part of the company's capital-markets plan, including compliance with Nasdaq listing rules and dilution management. Post-split, authorized shares will be reduced to 20,000,000, and outstanding shares will be approximately 649,914.

Aethlon Medical, Inc. announced the pricing and closing of a follow-on public offering, raising gross proceeds of $4.0 million. The offering included common stock, common warrants, pre-funded warrants, and placement agent warrants, priced at $0.71 per unit. The net proceeds of approximately $3.335 million will be used for general corporate purposes, including research and development, clinical trials, and working capital.

Aethlon Medical Inc. filed an amendment to its S-1 registration statement, detailing estimated expenses for the securities issuance totaling $450,381.52, with legal fees being the largest component. The filing also disclosed recent unregistered securities sales, including a December 2025 private placement involving pre-funded warrants and common stock warrants, and the exercise of existing warrants by an institutional investor. Additionally, the company granted 87,260 restricted stock units (RSUs) to non-employee directors in March/April 2026, valued at approximately $200,000.

Aethlon Medical, Inc. filed an S-1 registration statement for a best-efforts public offering of up to 6,000,000 shares of common stock and accompanying warrants, aiming to raise up to $12,000,000. The offering price is $2.00 per unit, with estimated net proceeds of $11,220,000 before expenses. The company also provided updates on its Hemopurifier device, including progress in its Australian oncology trial, pre-clinical research, and its FDA Breakthrough Device designation for cancer and viral infections.

Aethlon Medical is advancing its Hemopurifier, a clinical-stage immunotherapeutic device with FDA "Breakthrough Device" designation for oncology and life-threatening infectious diseases. The company is progressing with a safety, feasibility, and dose-finding clinical trial in Australia for advanced/metastatic cancer patients, having completed the first two cohorts without serious adverse events. To support operations and clinical development, Aethlon recently raised approximately $1.9 million in gross proceeds through an at-the-market (ATM) offering. However, the company's financial statements for fiscal year 2026 carry a going concern qualification, highlighting the need for additional financing and the speculative nature of investment.

Aethlon Medical, Inc. announced its financial results for the fiscal year ended March 31, 2026, reporting a reduced net loss of $7.2 million compared to $13.4 million in the prior year, alongside a 21.9% decrease in operating expenses to $7.3 million. Key business updates include advancing their Australian oncology study into the final dosing cohort and strengthening the Hemopurifier intellectual property portfolio with new patents for coronavirus-related conditions. The company also reported $5.0 million in cash and cash equivalents as of March 31, 2026.